LADENBURG THALM/SH SH Raises Marker Therapeutics (NASDAQ:MRKR) Price Target to $19.00

Marker Therapeutics (NASDAQ:MRKR) had its price objective hoisted by LADENBURG THALM/SH SH from $11.00 to $19.00 in a research report report published on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Marker Therapeutics Price Performance

Shares of NASDAQ:MRKR opened at $4.01 on Monday. Marker Therapeutics has a one year low of $2.40 and a one year high of $6.16. The firm has a fifty day moving average price of $3.15 and a two-hundred day moving average price of $3.98.

Marker Therapeutics (NASDAQ:MRKR) last posted its earnings results on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter. Marker Therapeutics had a negative return on equity of 78.91% and a negative net margin of 278.27%. The business had revenue of $1.17 million for the quarter. Sell-side analysts forecast that Marker Therapeutics will post -1.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. Wedbush Securities Inc. grew its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned 0.78% of Marker Therapeutics worth $377,000 at the end of the most recent quarter. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.